Advertisement

Topics

Canakinumab reduces gout rate by more than half

07:00 EDT 14 Jun 2018 | European Pharmaceutical Review

gout-CV

The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half, compared to placebo, regardless of baseline serum urate level.

The post Canakinumab reduces gout rate by more than half appeared first on European Pharmaceutical Review.

Original Article: Canakinumab reduces gout rate by more than half

NEXT ARTICLE

More From BioPortfolio on "Canakinumab reduces gout rate by more than half"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Gout
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....